Generic Clearance for the Collection of Qualitative Data on Tobacco Products and Communications

ICR 202406-0910-003

OMB: 0910-0796

Federal Form Document

Forms and Documents
Document
Name
Status
Supplementary Document
2024-07-03
Supplementary Document
2024-06-20
Justification for No Material/Nonsubstantive Change
2022-11-18
Supplementary Document
2021-06-14
Supporting Statement B
2024-06-12
Supporting Statement A
2024-06-12
IC Document Collections
IC ID
Document
Title
Status
ICR Details
0910-0796 202406-0910-003
Received in OIRA 202211-0910-007
HHS/FDA CTP
Generic Clearance for the Collection of Qualitative Data on Tobacco Products and Communications
Extension without change of a currently approved collection   No
Regular 07/05/2024
  Requested Previously Approved
36 Months From Approved 07/31/2024
343,100 28,174
399,182 14,934
0 0

The Food and Drug Administration (FDA) is requesting approval of a new generic for collecting information through the use of qualitative methods for studies about tobacco products. FDA will employ qualitative research, including individual in-depth interviews (IDIs), small group discussions, and focus groups to explore knowledge and perceptions about tobacco-related topics with specific target audiences. FDA will only submit an individual generic collection for approval under this generic clearance if the individual collection meets the outlined conditions.

US Code: 21 USC 355 Name of Law: Family Smoking Prevention And Tobacco Control Act
   US Code: 21 USC 393 Name of Law: FFDCA
  
None

Not associated with rulemaking

  89 FR 1097 01/09/2024
89 FR 51534 06/18/2024
No

0

  Total Request Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 343,100 28,174 0 0 314,926 0
Annual Time Burden (Hours) 399,182 14,934 0 0 384,248 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
No
No
Our estimated burden for the information collection reflects an overall increase of 384,248 hours and a corresponding increase of 314,926 responses. We attribute this adjustment to the number of study responses used during the current approval and now estimated for the next three years. A greater number of qualitative studies will be conducted over the next three years due to the need to develop new creative messages and content. Recent years have seen a dramatic change in media. With the shift to digital media, FDA must adapt to communicate effectively in a digital environment. As digital tobacco use prevention/interventions are still in their infancy, we must better understand the types of digital channels available. To impact public health outcomes, we need to understand how to reach our intended audience. New foundational studies are needed (including those on digital metrics, measurement, and implementation). Additionally, we have also updated the cost burden estimate based on current Bureau of Labor and Statistics salary figures.

$1,029,504
Yes Part B of Supporting Statement
    Yes
    No
No
No
No
No
Jonna Capezzuto 301 796-3794 jonnalynn.capezzuto@fda.hhs.gov

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
07/05/2024


© 2024 OMB.report | Privacy Policy